| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.00078 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.00082 | 1 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.00073 | 1 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.00048 | 1 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.0025 | 1 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.00036 | 1 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.00081 | 1 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.00035 | 1 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.00037 | 1 |